Sign Out
Pregnancy: There are no adequate data from the use of cisatracurium in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonic/foetal development, parturition and postnatal development. The potential risk for humans is unknown.
Cisatracurium Kabi should not be used during pregnancy.
Breast-feeding: It is not known whether cisatracurium or its metabolites are excreted in human milk.
A risk to the breastfed infant cannot be excluded. Due to the short half-life, an influence on breastfed infant is not to be expected if the mother restarts breast-feeding after the effects of the substance have worn off. As a precaution breast-feeding should be discontinued during treatment and for at least 12 hours after administration of Cisatracurium Kabi.
Fertility: Fertility studies have not been performed.
